Actively Recruiting
Observational Study on Effectiveness and Safety of Cabozantinib in Adults with Previously Treated Neuroendocrine Tumors
Led by Ipsen · Updated on 2026-10-01
150
Participants Needed
41
Research Sites
61 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well cabozantinib works and how safe it is for adults with neuroendocrine tumors NETs, a type of cancer that can appear in various parts of the body. This study is focused on adults whose disease has continued to grow despite receiving at least one prior systemic treatment. The study takes place in regular hospitals and clinics in Germany and Austria and involves about 150 participants. Participants in this observational study will be taking cabozantinib as part of their usual care. No extra tests or procedures beyond routine medical visits, tests, and scans will be performed. Doctors will collect information on how the cancer responds to cabozantinib and how long participants stay on the treatment, along with monitoring side effects and quality of life. During the study, participants will be observed through their standard medical care visits. Researchers will gather data from routine medical tests, scans, and questionnaires about quality of life every three months for up to 18 months. They will measure disease control rates at 6 months, treatment duration, adverse events, and other clinical outcomes. The total follow-up period can last up to 18 months to monitor disease progression and treatment impact.
CONDITIONS
Brief Title
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Research Team
I
Ipsen Clinical Study Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here